Latest state legislative action concerning ephedrine alkaloid-containing supplements would limit their sale to "behind-the-counter" status and require labeling warn consumers that exceeding the recommended dose may lead to "heart attack and stroke." SB 397, introduced March 12 by Assemblywoman Jackie Speier, a San Francisco-area Democrat, is similar to legislation introduced by Susan Davis last session. That measure was vetoed by Gov. Gray Davis Sept. 30. Susan Davis currently represents California's 49th district in the U.S. House; her former health staffer now works for Speier. SB 397 was read once and sent to the Committee on Health & Human Services. A hearing is scheduled for April 4

California legislation requiring more stringent labeling for ephedrine-alkaloid dietary supplements was vetoed Sept. 30 by Gov. Gray Davis (D). The move came as a surprise to industry and to the office of Assemblywoman Susan Davis (D), who sponsored the bill.

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC